Ayala Pharmaceuticals, Inc. (ADXS)

Market Cap	35.79M +341.9%
Revenue (ttm)	13.00K -98.1%
Net Income	-48.07M
EPS	-7.99
Shares Out	59.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,591
Average Volume	13,024
Open	0.6000
Previous Close	n/a
Day's Range	0.6000 - 0.6195
52-Week Range	0.0011 - 0.8010
Beta	-4.02
RSI	66.59
Earnings Date	Apr 17, 2026

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers in Israel and the United States. The company is developing AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. The company was incorporated in 1987 and is based in Monmouth Junction, New Jersey.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 21
• Stock Exchange: OTCMKTS
• Ticker Symbol: ADXS